Irene Scarfò
- Oncology top 2%
- CAR-T cell therapy research 27
- Immunology top 5%
- Immune Cell Function and Interaction 5
- Biosimilars and Bioanalytical Methods 3
- Aging top 5%
- Genetics top 5%
- Virus-based gene therapy research 3
-
- CRISPR and Genetic Engineering 7
-
- Nanowire Synthesis and Applications 5
-
- Lymphoma Diagnosis and Treatment 4
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- Marcela V. MausAmanda A. BouffardAndrea SchmidtsRebecca C. LarsonMatthew J. FrigaultAna P. CastañoMark B. LeickStefanie R. Bailey
- Journals
- Blood (9 papers)Nature Biotechnology (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)
- Partner nations
- United StatesDenmarkItaly
In The Last Decade
Irene Scarfò
31 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 1.4k
- Business and International Management 64
- Immunology 553
- Aging 39
- Genetics 499
Countries citing papers authored by Irene Scarfò
This map shows the geographic impact of Irene Scarfò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Scarfò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Scarfò more than expected).
Fields of papers citing papers by Irene Scarfò
This network shows the impact of papers produced by Irene Scarfò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Scarfò. The network helps show where Irene Scarfò may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Irene Scarfò, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 23 | |
| 5 | CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursbreakdown → | 2022 | 225 |
| 6 | 2022 | 88 | |
| 7 | 2021 | 180 | |
| 8 | 2021 | 3 | |
| 9 | 2020 | 18 | |
| 10 | 2020 | 6 | |
| 11 | 2019 | 85 | |
| 12 | CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicitybreakdown → | 2019 | 426 |
| 13 | Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editingbreakdown → | 2019 | 453 |
| 14 | 2019 | 228 | |
| 15 | 2019 | 19 | |
| 16 | 2019 | 23 | |
| 17 | 2018 | 105 | |
| 18 | 2018 | 6 | |
| 19 | 2017 | 153 | |
| 20 | 2016 | 1 |
About Irene Scarfò
Irene Scarfò is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine, having authored 32 papers that have together received 2.2k indexed citations. Recurring topics across this work include CAR-T cell therapy research (27 papers), CRISPR and Genetic Engineering (7 papers), Immune Cell Function and Interaction (5 papers), Nanowire Synthesis and Applications (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Virus-based gene therapy research (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Oncology (1.4k citations), Business and International Management (64 citations) and Immunology (553 citations). Irene Scarfò has collaborated with scholars based in United States, Denmark and Italy. Frequent co-authors include Marcela V. Maus, Amanda A. Bouffard, Andrea Schmidts, Rebecca C. Larson, Matthew J. Frigault, Ana P. Castaño, Mark B. Leick, Stefanie R. Bailey, Bryan D. Choi and Bob S. Carter. Their work appears in journals such as Blood, Nature Biotechnology, Journal for ImmunoTherapy of Cancer, Oncotarget and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.